By upregulating AXL, DANCR activated the PI3K/Akt/NF-κB signaling pathway in glioma cells, and inhibition of this signaling pathway reversed the effect of DANCR on cisplatin resistance [119,120]. This evidence concerns the gene NFKB1 and central nervous system cancer.